SOURCE: Sensimed AG

Sensimed AG

January 22, 2013 07:56 ET

Sensimed to Actively Participate in the Coming Glaucoma 360 Conference and at the American Glaucoma Society in the USA

LAUSANNE, SWITZERLAND--(Marketwire - Jan 22, 2013) - Sensimed AG, the developer of a revolutionary contact lens (the SENSIMED Triggerfish®) for the continuous monitoring of fluctuations in intraocular pressure (IOP) to facilitate the management of glaucoma, announced today that the company will participate in two major glaucoma meetings taking place in San Francisco in February 2013.

Sensimed is proud to present its breakthrough technology at the Glaucoma 360 New Horizons Forum being held on Friday, February 1st, 2013 at the Palace Hotel, in San Francisco. The conference presented by the Glaucoma Research Foundation brings together key clinical, industry, financial and regulatory leaders in a unique exchange on research innovation and advances in glaucoma treatment. Globally, glaucoma is a leading cause of preventable blindness.

In addition, the company will present 4 scientific abstracts at the upcoming American Glaucoma Society (AGS) meeting from February 28th to March 3rd 2013 in San Francisco. The abstracts will be reporting on the use of the SENSIMED Triggerfish® in clinical studies.

FROM DEVICE TO KNOWLEDGE -- Sensimed AG, a Swiss company, has developed a non-invasive soft contact lens-based solution, the SENSIMED Triggerfish that revolutionizes glaucoma management by providing continuous 24 hour intraocular pressure (IOP) profiles as well as modeling and analysis of IOP patterns. The 24 hour IOP profiles, centralized on a registry together with patient and treatment information, are processed by powerful modeling and learning algorithms identifying pathological patterns that can be used to differentiate indication and to personalize treatment. Sensimed is directly positioned at the convergence between devices, treatment and information. The company believes that this global knowledge-building approach will enable ophthalmologists to better improve management of patients with potentially progressive glaucomatous disease.

For further information about Sensimed see:

About Glaucoma Research Foundation
Founded in 1978 and headquartered in San Francisco, Glaucoma Research Foundation is America's oldest and most experienced nonprofit dedicated solely to its mission: to prevent vision loss from glaucoma by investing in innovative research, education and support with the ultimate goal of finding a cure. Celebrating its 35th anniversary in 2013, Glaucoma Research Foundation has invested more than $40 million to advance essential research and education programs.

More information is available at

For further information about the AGS see:

The SENSIMED Triggerfish® is not approved for sale in the USA.

Sensimed at Glaucoma 360 and AGS:

Contact Information